Wegovy weight loss per week: what the evidence actually shows

Why there is no single 'per-week' figure for Wegovy

A flat weekly number is tempting but misleading. The STEP 1 trial (the cornerstone study for semaglutide 2.4mg, published in the New England Journal of Medicine) followed nearly 2,000 adults with obesity over 68 weeks. Average weight loss across the full period came to roughly 15% of starting weight. Divide that over 68 weeks and you get something like 0.2–0.4 kg per week on average. But that average conceals a pattern that looks nothing like a straight line.

The early weeks, when doses are lowest, often produce the smallest changes on the scales. The titration schedule moves from 0.25mg through several steps to the 2.4mg maintenance dose, with roughly four weeks at each level. During those low-dose phases, the appetite-suppressing effect is building rather than running at full strength. Some people lose several kilograms in the first month; others see very little movement until dose increases kick in.

The common misconception that a slow first few weeks means Wegovy isn't working deserves a gentle correction here. Slower early weeks are part of the pharmacology, not a signal that treatment has failed. Sticking to the titration plan is what matters. If you want to understand the week-by-week shape of the treatment journey in more detail, our guide to Wegovy weight loss by week maps this out stage by stage.

What the evidence says about different time points

Looking at specific windows tells a more useful story than a blanket weekly average. Data from the STEP programme (referenced in NICE's appraisal of semaglutide for weight management (TA875)) shows that meaningful, measurable loss is typically established by 12 weeks, with the steeper part of the curve arriving as higher maintenance doses bed in.

At six weeks, many people are still in the mid-titration phase and total loss may be modest, a few kilograms at most. By 12 weeks on a stable maintenance dose, the cumulative picture starts to look more substantial. What to expect at the 12-week mark covers that stage specifically, including what a prescriber might review if progress is slow.

For the 7.2mg single-dose pen approved by the MHRA in April 2026, trial data showed approximately 20.7% average weight loss over 72 weeks, a meaningful step up from the 2.4mg results and worth noting for people considering the higher-dose pathway once it is clinically appropriate. That decision sits firmly with the prescriber, not the patient.

One more honest point: weight fluctuates by 1–2 kg day to day because of fluid, food volume and hormonal shifts. Weighing at the same time of day, once a week, under the same conditions, gives a far cleaner read than daily checks.

The factors that shift your individual weekly rate

Two people on the same dose in the same week rarely lose at the same rate. Several things drive that difference, and understanding them matters more than chasing a fixed weekly target.

Starting weight plays a role: percentage-based loss tends to look similar across the trial population, but in absolute kilograms, a heavier starting point often produces larger early numbers. Diet quality alongside treatment also matters; semaglutide reduces appetite, but what you eat within that reduced appetite still shapes outcomes. Protein adequacy, hydration and fibre all feature in NHS healthy eating guidance and become more relevant, not less, when overall food intake drops.

Physical activity affects the composition of weight lost. Without resistance training, some of the loss may come from lean muscle as well as fat. That is not unique to Wegovy (it is a feature of significant calorie deficits generally) but it is worth building movement in from early on rather than adding it later.

Underlying health conditions, other medications and how consistently doses are taken on schedule all feed into the picture too. For an overview of how Wegovy fits into broader weight management approaches, including what lifestyle changes typically run alongside it, that context is worth reading before you start.

When slow weeks signal something worth reviewing

Most plateaus are temporary and resolve as doses increase or as the body adapts. Genuine lack of response is defined clinically as less than 5% weight loss after six months on the maintenance dose, that is the threshold NICE sets for reviewing whether to continue treatment.

Reaching that threshold is not a failure of effort; it is a clinical data point that prompts a prescriber conversation. Factors like thyroid function, medications that promote weight gain, or a dose that was not titrated to the highest tolerated level may all be relevant. If you have seen no movement at week five, that page covers what is normal and what warrants a closer look.

Our prescribers review every repeat order before it goes out. If the trajectory is not tracking as expected, that review is the moment to raise it. The broader picture of what drives weight loss on Wegovy and how the six-week point typically looks are both useful alongside this page.

If you're considering starting treatment and want to understand whether Wegovy might be appropriate for you, speak to our prescribers through a free same-day consultation.